Comparison of Safety and Efficacy of Intravitreal Ziv-Aflibercept Vs Bevacizumab for the Treatment of Macular Edema
Aflibercept
DOI:
10.36351/pjo.v36i3.1014
Publication Date:
2020-07-08T12:40:10Z
AUTHORS (5)
ABSTRACT
Purpose: To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for management edema caused by different retinal pathologies.
 Study Design: Comparative interventional study.
 Place Duration Study: Lahore General Hospital, Lahore, from July 2018 to June 2019.
 Material Methods: Patients with resistant, center involving macular due diabetes, vein occlusion age related degeneration were recruited. Complete ocular examination was performed. All patients randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) IVB bevacizumab). Each eye underwent injection 0.05 ml fresh filtered ziv-aflibercept (1.25 mg) or Bevacizumab. Outcome measured in terms variation central thickness (CMT) also best corrected visual acuity (BCVA) at 3 months.
 Results: Total 156 eyes 136 completed whole duration included results. The mean baseline CMT 510 μm (± 94 μm) group 493μm (±102 (P = 0.94). BCVA (log MAR) 0.78 (Snellen's equivalent 6/36) 0.70 6/30) 0.78). Central significantly reduced 1st, 2nd 3rd month < 0.001).
 Conclusion: Intravitreal is safe more effective than treatment diabetes mellitus, wet degeneration.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....